Discrepancy between patient-reported quality of life and the prognostic assessment of Japanese patients hospitalized with acute heart failure.


Journal

Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 06 12 2018
accepted: 08 03 2019
pubmed: 20 3 2019
medline: 14 2 2020
entrez: 20 3 2019
Statut: ppublish

Résumé

Patient-reported quality of life (PRQL) is a primary therapeutic target for patients with chronic heart failure (HF) and is associated with long-term prognosis. However, its utility in hospitalized HF (HHF) patients in the acute setting remains unclear. We aimed to assess the utility of PRQL (the Kansas City Cardiomyopathy Questionnaire [KCCQ]) in HHF patients and its association with long-term prognosis as well as with the clinical risk score (Get With The Guidelines-Heart Failure [GWTG-HF] risk score). PRQL was evaluated using the KCCQ in consecutive 114 HHF patients. Its association with the composite outcome of all-cause mortality or HF readmission within the first year after discharge was analyzed. Furthermore, its distribution by the clinical risk score (GWTG-HF) was evaluated using Pearson's correlation coefficient. The median KCCQ was 34.9, but was widely distributed (interquartile range 23.7-56.8). After adjustment for known prognostic indicators, the KCCQ was not an independent predictor of the composite outcome within the first year (group with high vs. low KCCQ scores: hazard ratio, 0.67; 95% confidence interval 0.26-1.71). There was no significant correlation between the KCCQ and the GWTG-HF risk score. In conclusion, PRQL during the acute phase of HF was significantly impaired and also varied widely, irrespective of patient characteristics or severity. PRQL assessment and risk prediction for HHF patients in the acute setting seemed to provide two distinct types of information for health care providers.

Identifiants

pubmed: 30887105
doi: 10.1007/s00380-019-01378-1
pii: 10.1007/s00380-019-01378-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1464-1470

Subventions

Organisme : Japan Agency for Medical Research and Development (JP)
ID : 201439013C
Organisme : Health Labor Sciences Research Grant
ID : 14528506
Organisme : Grant-in-Aid for Young Scientists
ID : 18K15860

Références

J Am Coll Cardiol. 2000 Apr;35(5):1245-55
pubmed: 10758967
Circulation. 2004 Aug 3;110(5):546-51
pubmed: 15262843
J Am Coll Cardiol. 2006 Feb 21;47(4):752-6
pubmed: 16487840
Circulation. 2006 Mar 21;113(11):1424-33
pubmed: 16534009
JAMA. 2007 Mar 28;297(12):1332-43
pubmed: 17384438
JAMA. 2007 Nov 7;298(17):2009-19
pubmed: 17986694
Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32
pubmed: 20123668
Eur J Heart Fail. 2010 Apr;12(4):367-74
pubmed: 20197265
Circ J. 2011;75(7):1661-9
pubmed: 21532181
Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):389-98
pubmed: 21693723
N Engl J Med. 2011 Jul 7;365(1):32-43
pubmed: 21732835
Lancet. 2013 Jan 5;381(9860):29-39
pubmed: 23141816
Curr Cardiol Rev. 2013 May;9(2):112-22
pubmed: 23597295
Circ J. 2013;77(9):2209-17
pubmed: 23955345
J Card Fail. 2014 Jan;20(1):18-22
pubmed: 24296380
JACC Heart Fail. 2013 Dec;1(6):540-7
pubmed: 24622007
Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):469-76
pubmed: 26307129
Am Heart J. 2016 Jan;171(1):33-9
pubmed: 26699598
JACC Heart Fail. 2016 Mar;4(3):165-75
pubmed: 26874386
Cardiol Res Pract. 2016;2016:4571201
pubmed: 27872790
BMC Cardiovasc Disord. 2017 Mar 14;17(1):78
pubmed: 28288574
J Am Coll Cardiol. 2017 Aug 8;70(6):776-803
pubmed: 28461007
Heart Lung. 2017 Jul - Aug;46(4):293-299
pubmed: 28558929
Circ Heart Fail. 2017 Aug;10(8):null
pubmed: 28784687
JAMA Cardiol. 2017 Dec 1;2(12):1315-1321
pubmed: 29094152
J Card Fail. 2019 Jul;25(7):561-567
pubmed: 30099192
J Am Heart Assoc. 2018 Sep 18;7(18):e008687
pubmed: 30371201
Circulation. 1993 Jul;88(1):107-15
pubmed: 8319323

Auteurs

Satoshi Shoji (S)

Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Yasuyuki Shiraishi (Y)

Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Mitsuaki Sawano (M)

Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Yoshinori Katsumata (Y)

Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Shinsuke Yuasa (S)

Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Takashi Kohno (T)

Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Keiichi Fukuda (K)

Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

John A Spertus (JA)

Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.
University of Missouri Kansas City, Kansas City, MO, USA.

Shun Kohsaka (S)

Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. sk@keio.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH